The synthesis of a series of imidazole styrylindoles and sulfonyl styrylindoles derivatives is described. Evaluation of binding affinity and inhibitory activity against CYP24A1 identified the imidazole styrylindoles as potent inhibitors with activity greater or comparable with the standard ketoconazole.  Computational studies identified key enzyme binding interactions.
Introduction
The most biologically active form of vitamin D 3 , 1,25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 , calcitriol, 1) has an important role in the regulation of cell proliferation and differentiation [1] in addition to the key role of calcitriol in the regulation of calcium homeostasis and bone metabolism [2] , [3] . Serum levels of calcitriol have been associated with the prognosis of several cancers, with higher serum levels associated with improved prognosis [4] , [5] , [6] and lower levels associated with an increased risk and poorer prognosis [7] , [8] , [9] , [10] . The serum level of calcitriol is tightly regulated in a short feedback loop by two cytochrome P450 enzymes, the 1-hydroxylase CYP27B1 that promotes synthesis of calcitriol and the 24-hydroxylase CYP24A1 that inactivates calcitriol by metabolism [11] , [12] . Lower calcitriol levels is directly linked to high expression of CYP24A1 with increased CYP24A1 levels resulting in increased metabolism of calcitriol significantly reducing the circulating calcitriol and therefore the antiproliferative or prodifferentiation effects [13] , [14] , [15] , [16] .
Inhibition of CYP24A1 is therefore an attractive strategy to enhance endogenous circulating calcitriol and/or increase the half-life of exogenously administered calcitriol or vitamin D therapeutic. Studies using the non-specific CYP inhibitors, ketoconazole or liarozole in combination with calcitriol in prostate and breast cancer cell lines resulted in increased half-life of calcitriol and enhanced antiproliferative effect [17] , [18] . Similarly studies using CYP24A1 inhibitors, the isoflavone genistein and a novel tetralone derivative, greatly enhanced the apoptotic and differention effect of calcitriol in prostate cancer cell lines [19] , [20] . Our previous research on non-vitamin D CYP24A1 inhibitors [20] , [21] , [22] indicated the importance of a hydrophobic group or chain to allow complete fill of the hydrophobic channel of the CYP24A1 enzyme active site. In the development of the azole inhibitors, a styryl group was found to be optimal for inhibitory activity [21] ( Figure 1 ) resulting in compounds with activity comparable with the standard To include a compound for testing with a sulfinate bond, 1-(3-benzenesulfonyl-propyl)-4-styryl-1H-indole (20) was prepared on reaction with bromide (4a, n = 3, R = H) with benzene sulfinic acid sodium salt following described methodology (Scheme 2) [26] , [27] . styryl derivates (12 and 13) . Substitution of the styryl aromatic ring (R = H or OCH 3 ) did not affect the inhibitory activity. inhibitory activity compared with the standard ketoconazole (Table 1) . In this series the substitution of the styryl aromatic ring (R = H or OCH 3 ) did have an effect with the unsubstituted derivatives (18a, 19a, 20 and 23a) displaying greater inhibitory activity than the dimethoxy derivatives (18b, 19b and 23b).
CYP27B1 Enzyme Inhibition and Selectivity
Inhibition assay of CYP27B1 was performed in a similar way to the CYP24A1 assay as previously described [23] , and the resulting cell-free assay system applied in the screening of the compounds to measure Ki and IC 50 (Table 2) .
Compounds with good binding and inhibitory activity against CYP24A1 also displayed similar properties against CYP27B1. A small selectivity was observed for CYP24A1 with the indole imidazole with a lateral four carbon chain (7a) displaying the best selectivity (selectivity CYP27B1/CYP24A1 = 1.8) comparable with the standard, ketoconazole (selectivity CYP27B1/CYP24A1 = 1.7), although two of the derivatives in this series (6b and 13) showed a small selectivity for CYP27B1. 
Discussion
The indole-imidazole derivatives were prepared using a 4-step synthetic pathway. The six compounds (6a, 6b, 7a, 7b, 12 and 13, Table 1 ) showed a very interesting activity in the CYP24A1 enzymatic assay, which is comparable to our (E)-N-(2-(1H-imidazol-1-yl)-2-phenylethyl)-4-styrylbenzamides family previously reported [28] . The inhibition assay would suggest that the length of the lateral chain and position of the styrene on the indole ring are important to activity. The 3 carbon derivatives have lower activity, whereas the introduction of an extra carbon on the lateral chain results in an increase in inhibitory activity up to 2-fold. Substituting a 5-indole as the central core instead of the 4-indole results in a decrease in inhibitory activity.
In order to provide a rational explanation for the observed enzymatic data, flexible alignment and molecular docking studies were performed using MOE 2010 [29] and LeadIT2.1.2 [30] . All the molecular modeling studies were performed using a CYP24A1 homology model built using a rat CYP24A1 crystal structure [31] as a template and the amino acid sequence of the human isoform following a previous published homology model technique [32] . After performing a molecular docking of the most promising inhibitor (24: IC 50 = 0.11 M; Ki = 7.8 nM; CYP24A1/CYP27B1 selectivity = 3.3) from the previously reported (E)-N-(2-(1H-imidazol-1-yl)-2-phenylethyl)-4-styrylbenzamides [28] in the enzyme active site (Figure 2 ), its active binding conformation pose was kept rigid while a flexible alignment was executed using a database of the six indole-imidazole derivatives. Flexible alignment is a technique which allows determination of the best alignment in terms of internal strain and overlap of different molecular features (e.g.: aromatic
features, H-bond donors/acceptors, etc.) [33] . Using this molecular modeling tool the alignment of the indole-imidazole derivatives with the 24 binding pose conformation were evaluated and an interesting relation was found between the flexible alignment results (see Table 3 ) and the enzymatic inhibition assay data. The most active compound in the series, 7b, presents 4 carbons in the lateral chain and the 4-indole as central core. Figure 3A , shows the alignment between 7b (yellow) and 24 (lilac). The imidazole, the 3,5-dimethoxy phenyl ring and the benzyl portion of the indole core of 7b overlap perfectly with the corresponding groups of 24, with 7b perfectly spatially aligned with our reference compound. Moreover, as reported in Table 4 , this conformation has the lowest S value (sum of the internal energy of the ligand [U] and the similarity score [F] ) and therefore is the best in terms of overlapping score. The low S value is due to the good internal energy of the ligand pose (U value) and the high similarity score (F value) meaning that the 7b conformation obtained is not forced in the first case and that the two molecules have a high shape/functional group similarity in the second case. Figure 3B ) and its S value is the second in the ranking.
The absence of the 3,5-dimethoxy substituents results in a decrease in the similarity score F with 24 leading to a slightly higher S value.
The 3 carbons derivatives 6b (green) and 6a (white), present a higher S value as a consequence of the unfavorable visual overlapping ( Figure 3C and 3D respectively). [31] . This disposition allows the imidazole ring to be optimally positioned for the interaction between its nitrogen lone pair and the haem iron. 7b is disposed in the active site in the same manner as 24, occupies the full length of the enzyme channel and forms a H-bond between its 3-methoxy group and Gln82 as found for our reference compound ( Figure 4 ). The docking studies of these two derivatives confirmed our initial deduction and the possible connection between the spatial alignment with 24 and the capacity to entirely sit in the enzyme active site. 13 was not able to occupy the active site due to its structural flexibility conferred by the presence of the stryryl ring in position 5 instead of 4 ( Figure 7 ). As previously mentioned, the inability to accommodate the entire active site can result in a decrease of CYP24A1 enzymatic inhibition. The replacement of the imidazole in both the indole-sulfonate and indole-sulfonamide series resulted in a notable decrease in inhibitory activity. These results underline the key role of the imidazole ring in the binding to the CYP24A1 haem group [34] , [35] .
In fact, the higher structural similarity among these three families suggests that the decrease in activity in these two last series of compounds is a consequence of the 
Conclusions
We have developed methods for the preparation of novel styrylindoles (imidazole, The challenge in the development of CYP24A1 inhibitors is achieving selectivity between CYP24A1 and CYP27B1. In the absence of an available crystal structure of CYP27B1 it is essential to develop a reliable homology model to allow exploitation of any differences between the active sites of CYP24A1 and CYP27B1, however with the similarity of the two substrates, 1,25(OH) 2 D 3 and 25(OH) D 3 respectively, any differences are likely to be subtle. This is the current focus of our investigations using the styrylindoles (e.g. 7a) and styrylbenzamides (e.g. 24) as lead compounds for further development. followed by charring on a hotplate. Melting points were determined on an electrothermal instrument and are uncorrected. All solvents were dried prior to use and stored over 4Å molecular sieves, under nitrogen. All compounds were more than 95% pure. (7 mmol) and NaH (60% dispersion in mineral oil) (21 mmol) in dry DMF (10 mL) were cooled to 0˚C using an ice bath and stirred for 5 min. 1,3-Dibromopropane or 1,4-dibromobutane (70 mmol) was added and the reaction mixture was stirred for 10 min. On completion, the solvent was evaporated under reduced pressure and the residue was dissolved in CH 2 Cl 2 (100 mL), washed with water (2 x 50 mL) and dried over MgSO 4 . The organic layer was then evaporated to dryness and the residue was purified by flash column chromatography to obtain the pure product. 
Experimental

Materials and Methods
1-(3-Bromopropyl)-4-styryl-1H-indole (4a, R = H).
4-(3,5-Dimethoxystyryl)-1-(4-bromobutyl)-1H-indole (5b, R = OCH 3 ).
Purified by flash column chromatography eluting with petroleum ether-EtOAc 100:0 
1-(4-Bromobutyl)-5-styryl-1H-indole (11).
Purified by flash column chromatography eluting with petroleum ether-EtOAc 100:0 v/v increasing to 98:2 v/v.
Obtained in 84% yield as a yellow wax. TLC (9:1 Petroleum ether/EtOAc, Rf = 0.44). 
General method for the preparation of imidazoles 6, 7, 12 and 13.
A suspension of NaH (60% dispersion in mineral oil) (6 mmol) in dry DMF (15 mL) was stirred and heated at 60˚C for 5 min. Imidazole (6 mmol) was added and the reaction mixture was heated at 60˚C for 1 h. The reaction mixture was cooled to room temperature and the styryl-1-bromoalkyl-1H-indole (4, 5, 10 or 11) (3 mmol) was added. The reaction mixture was heated at 60˚C overnight and then hydrolysed by adding H 2 O (100 mL). The aqueous layer was extracted with EtOAc (3 x 100 mL); the organic layers were collected and dried over MgSO 4 . The solvent was then evaporated to dryness and the residue was purified by flash column chromatography (petroleum ether-EtOAc 50:50 v/v then CH 2 Cl 2 -MeOH 100:0 v/v increasing to 98:2 v/v) to obtain the pure desired product. 
1-[3-(1H-Imidazol-1-yl)propyl]-4-styryl-1H-indole (6a, R = H).
1-[4-(1H-Imidazol-1-yl)butyl]-4-styryl-1H-indole (7a, R = H).
1-[3-(1H-Imidazol-1-yl)propyl]-5-styryl-1H-indole (12
1-(4-Azido-butyl)-4-styryl-1H-indole (15a, R = H).
1-(4-Azido-butyl)-4-(3,5-dimethoxystyryl)-1H-indole (15b, R = OCH 3 ).
Obtained in 57% yield as an orange glue. 
3-[4-(3,5-Dimethoxystyryl)-indol-1-yl]propylamine (16b, R = OCH 3 ).
Obtained in 72% yield as a yellow glue. TLC (1:1 Petroleum ether/EtOAc Rf = 0.15). 
4-[4-(3,5-Dimethoxystyryl)-indol-1-yl]butylamine (17b, R = OCH 3 ).
Obtained in 79% yield as a yellow glue. TLC (1:1 Petroleum ether/EtOAc Rf = 0.16). (20) . washed with aqueous satured NaHCO 3 (50 mL) and the organic layer was separated.
Synthesis of (E)-3-(4-styryl-1H-indol-1-yl)propyl benzenesulfinate
The aqueous layer was extracted with CH 2 Cl 2 (50 mL) and both organic layers were washed with aqueous 1 M HCl (50 mL). The organic layer was washed with aqueous saturated NaHCO 3 (50 mL) and then dried over MgSO 4 . The solvent was evaporated under vacuum.
Toluene-4-sulfonic acid 3-(4-styryl-indol-1-yl)-propyl ester (23a, R = H).
A yellow glue was obtained in 53% yield after purification by flash column chromatography (petroleum ether -ethyl acetate 100:0 v/v increasing to 90:10 v/v). 
CYP24A1 and CYP27B1 inhibition assay
Inhibition of CYP24A1 was carried out as described previously [23] . Inhibition assay of CYP27B1 was performed in a similar way to that of CYP24A1 as previously described [23] . The concentration of substrate 25(OH)D 3 was 2.5 μM and K M for CYP27B1 was 0.48 μM.
Molecular Modelling
Docking studies were performed using LeadIT2.1.2 docking program by BioSolve.IT [29] . The important amino acid residues of the active pocket (Gln82, Ile131, Trp134, Met246, Ala326, Glu329, Thr330, Val391, Phe393, Thr394, Ser498, Gly499, Tyr500) [32] were selected and then the selection was extended to 12 Å in order to include in the docking site the haem iron region and the access tunnel to the catalytic site. A ligands database in mol2 format, prepared using MOE [30] , was used as input for the docking calculations. The iron atom of the catalytic site was set as essential pharmacophoric feature. Ligand docking was performed using the default values and no water molecules were considered. Ten output solutions were obtained from each compound and visual inspection in MOE was used to identify the interaction between ligand and protein.
The flexible alignment studies were performed using MOE 2010. The MOE flexible alignment tool generates different possible conformations for each of the different six molecules present in the input mol2 format database that could overlap with the assigned template. The quality of the alignment is evaluated by a score which is a sum of the internal strain of the obtained conformation (the smaller, the better) and the overlap of molecular features (aromatic regions, donors/acceptors). MOE, for each alignment performed, evaluates the average internal energy of the ligands U, the similarity score F (the lower value is the better two structures overlap) and the value S (sum of U and F values obtained for each alignment). A good alignment should present a dU value (the average strain energy of the molecules in the alignment in kcal/mol) lower than 1 kcal/mol meaning that the obtained conformation are not energetically disadvantaged. In our case, we kept our template rigid and the flexible alignment of the six compounds was run. The obtained data with a dU of 0.0 (no energy penalty) were kept and ranked according to the lowest S value.
